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Graft-versus-host-disease (GvHD) prophylaxis included Tacroli-
mus based (n52), Cyclosporine based (n27) and other regimens
(n2). 37 patients received PBPC and 44 received BM transplant.
The overall survival (OS), disease free survival (DFS) and non-
relapse mortality (NRM) at 1 year were 38%, 31%, and 32%
respectively. Results of the univariate analysis for various potential
prognosis factors are shown in the Table. First CR of more than 1
year and performance status of 0 at transplantation were predictors
of better OS, and DFS at 1 year. Conclusion: In patients with
untreated First Relapse AML/MDS, longer duration of ﬁrst CR
and better performance status were predictors of better outcomes
of allogeneic HSCT in this patient population. These patients
could be considered for allogeneic HSCT upon their ﬁrst relapses.
Development of better treatment strategies may help to improve
outcomes in other patients without these good prognostic factors.
Univariate Analysis of Prognostic Factors for Outcomes
Variable
OS at
1 Year
p
Value*
DFS at
1 Year
p
Value*
NRM at
1 Year
p
Value*
AML 33% 25% 30%
MDS 29% NS 21% NS 48% NS
AML/MDS 43% NS 43% NS 33% NS
Duration of first CR
>1 year 66% 61% 16%
Duration of first CR
<1 year 30% 0.01 26% 0.003 25% 0.9
Absence of PB blast
at relapse 45% 38% 31%
Presence of PB blast
at relapse 37% NS 35% NS 25% NS
BM Leukemic
Infiltrate <10% 32% 25% 33%
BM Leukemic
Infiltrate >10% 52% NS 40% NS 18% NS
Poor risk cytogenetic
results at relapse 34% 24% 37%
Other cytogenetic
results at relapse 41% NS 40% NS 25% NS
Performance status 0
at transplant 46% 46% 16%
Performance status
>0 at transplant 32% 0.02 25% 0.01 31% 0.1
*By log rank test, NS indicates not signiﬁcant.
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DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE DEPENDS UPON
ESTABLISHMENT OF COMPLETE DONOR T CELL CHIMERISM AFTER T
CELL DEPLETED, REDUCED INTENSITY HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Hardy, N.M.1; Steinberg, S.M.2; Krumlauf, M.1; Cvitkovic, R.3; Cas-
tro, K.1; Hakim, F.1; Carter, C.4; Read, E.J.4; Leitman, S.4; Gress, R.1;
Bishop, M.R.1 1. National Institutes of Health/National Cancer Insti-
tute/Experimental Transplantation and Immunology Branch, Bethesda,
MD; 2. National Institutes of Health/National Cancer Institute/Biosta-
tistics and Data Management Section, Bethesda, MD; 3. Brigham
Young University, Provo, UT; 4. National Institutes of Health/Clinical
Center/Department of Transfusion Medicine, Bethesda, MD.
Introduction: As part of a protocol to study the inﬂuence of host
immunodepletion on engraftment, in which we administered DLI
after TCD-RIST, we were able to analyze the effect of donor
engraftment on the development of GVHD. Methods: Eighteen
patients with metastatic breast cancer were enrolled. Each received
1–2 cycles of cyclophosphamide (600 mg/m2/day) and ﬂudarabine
(30 mg/m2/day) for four days, to a target CD4 count of 50 cells/l.
Pts then received ﬂudarabine (30 mg/m2/day) and cyclophospha-
mide (1200 mg/m2/day) from day 6 to 3 prior to matched
sibling donor allotransplantation. The allografts were TCD by
sequential CD34 positive-selection and negative selection using
monoclonal antibodies against CD2, CD6, and CD7, with T cell
add-back to an adjusted dose 1  105 CD3 cells/kg. Pts received
a minimum of 5  106 CD34 cells/kg. Pts received full dose
cyclosporine A (CsA) until day 28 followed by tapering over
twelve days. Pts without GVHD received 1, 5, and 10 106 CD3
cells/kg on days 42, 70, 98, respectively. Pts were eligible to
receive additional DLI beyond day 98. Results: Two pts died
before day 28 and were not included in the analysis. All remaining
pts achieved complete donor T cell engraftment upon completion
of scheduled DLI. Nine pts (56%) developed grade II-IV acute
GVHD. Four of 14 evaluable pts (29%) developed chronic
GVHD, two extensive. Development of GVHD was associated
with complete (90%) donor T cell chimerism (p
.005); only one
patient with mixed T cell chimerism developed GVHD. There was
no association between the absolute lymphocyte count and either
GVHD or establishment of chimerism. Three of 16 pts (19%) did
not receive DLI due to GVHD. Five of 16 pts (31%) received one
or two of three planned DLI. Six received more than three DLI,
for disease control. There was no correlation between the number
or dose of DLI administered and the development of GVHD.
Conclusions: In marked contrast to reports of non-myeloablative
HST, we found a strong association between complete donor T
cell engraftment and the development of GVHD following RIST,
suggesting a suppressive effect of recipient T cells. This could be
from direct cytotoxicity or the activity of a regulatory subset,
controlling alloreactivity until full donor chimerism is established.
While lower rates of GVHD following RIST have been reported,
T cell chimerism may be confounding.
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ESTABLISHMENT OF A NATIONAL CORD BLOOD BANKING NETWORK
THROUGH THE NATIONAL MARROW DONOR PROGRAM
Kurtzberg, J.1; Creer, M.2; Halet, M.3; Welte, K.3; Boo, M.3; Confer,
D.3; Chell, J.3, for the members of the NMDP Cord Blood Banking
Network. 1. Duke University Medical Center, Durham, NC; 2. St.
Louis Cord Blood Bank, St. Louis, MO; 3. National Marrow Donor
Program, Minneapolis, MN.
The majority of patients in need of a bone marrow or stem cell
transplant do not have a matched related family member to serve as
their donor. Over 17 years ago, the National Marrow Donor
Program was established to provide a registry of volunteer adult
unrelated donors for patients in need of a hematopoietic stem cell
transplant. The NMDP lists 5,000,000 adult donors and has
facilitated 20,000 transplants to date. Despite this success, ap-
proximately 30% of Caucasian and 80% of African American and
Asian patients are unable to ﬁnd a suitably matched adult volunteer
donor. Over the past 11 years, studies have demonstrated that
banked unrelated donor, partially HLA mismatched umbilical cord
blood (UCB) could serve as an alternative source of hematopoietic
stem and progenitor cells for allogeneic transplantation. UCB may
increase access to transplantation therapy for patients lacking a
matched donor, particularly those of ethnic or racial minority
backgrounds. To date, approximately 14 public cord blood banks
have been established in the U.S. creating a heterogeneous inven-
tory of approximately 50,000 cord blood units (CBUs). Uniform
standards were not followed by the different banks and all lack
sufﬁcient inventory of HLA diverse, large CBUs. Over the past
year, 13 U.S. banks have voluntarily joined together to create a
network of public cord blood banks as part of the NMDP. A
steering committee was established comprised of cord blood bank
directors, transplanters, experts in HLA, an ethicist, representation
from FDA and HRSA with experts in information technology (IT)
and administrative support from the NMDP. The committee
adopted uniform standards for cord blood donor recruitment and
screening, donor education and consent, medical histories, infec-
tious disease and hemoglobinopathy testing, cord blood collection,
processing, testing, cryopreservation and storage. Subcommittees
for quality standards, collection, education, research, IT, econo-
mies, bank/transplant center interface and proﬁciency testing were
developed with active ongoing agendas. Management systems for
UCB donor searches, collection, analysis and distribution of clin-
ical outcomes data back to the banks are being established. This
NMDP Cord Blood Banking Network represents the ﬁrst coop-
erative effort unifying the majority of public cord blood banks in
the U.S. Importantly, all CBUs will be listed on a single web-based
search registry providing easy access to all NMDP Transplant
Centers.
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